158 - Combining SBRT with GM-CSF and Peg-IFNa to Induce Abscopal Effects In Previously Treated Patients with Metastatic Thymic Tumors: A Single Institution, Phase II Trial

08:40am - 08:50am ET

Room 157

Presenter(s)

Min Fan, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Shanghai

M. Fan¹, B. Wang², H. Li³, J. Wen², and J. Chen⁴; ¹Fudan University Shanghai Cancer Center, Shanghai, China, ²Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, ³Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China, ⁴Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

Purpose/Objective(s):

After the failure of multi-line treatment, patients with stage ? thymic tumors have a poor prognosis and few therapeutic options. Combining stereotactic body radiotherapy (SBRT) with granulocyte-macrophage colony-stimulating factor (GM-CSF) and Pegylated interferon-a (Peg-IFNa) may induce abscopal effects and improve prognosis.

Materials/Methods:

We conducted this open-label, single-arm, phase ? trial to evaluate SBRT plus GM-CSF and Peg-IFNa in previously treated patients with stage ? thymic tumors. A 21-day treatment cycle consisted of SBRT delivered to one metastatic lesion with 30 Gy in 5 fractions from day 1, synchronous subcutaneous injection of GM-CSF 125 µg/ m² once daily for 14 days, and subcutaneous injection of Peg-IFNa 90 µg on day 8. If the patient has more than two metastatic lesions, another treatment cycle was repeated. After the completion of 1 or 2 treatment cycles, Peg-IFNa therapy was maintained for at least half a year with a subcutaneous injection of 90 µg once a month. The two primary endpoints were the proportion of patients with abscopal effects and the objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS), and therapeutic safety.

Results:

A total of 20 patients from March 2021 to September 2022, were enrolled in this trial, with 1 (5.0%) type A thymoma, 2 (10.0%) type B1 thymoma, 2 (10.0%) type B2 thymoma, 1 (5.0%) type B3 thymoma, 12 (60.0%) thymic squamous cell carcinoma and 2 (10.0%) thymic neuroendocrine tumor. At a median follow-up of 18.6 months, 8 (40.0%) out of 20 patients had abscopal effects, and the ORR was 45.0%. The median OS had not been attained yet. The median PFS was 9.0 months. We observed that patients with abscopal effects tended to have longer OS and PFS than those without abscopal effects (Figure 1). 3 patients (15.0%) experienced Grade 3 treatment-related adverse events (CTCAE version 5.0), among which cardiac insufficiency compelled 1 patient (5.0%) to drop out of treatment.

Conclusion:

Combining SBRT with GM-CSF and Peg-IFNa was well tolerated with acceptable toxicity and may represent a promising salvage therapy for previously treated patients with stage ? thymic tumors. The occurrence of abscopal effects is likely to improve patient outcomes.